The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics
VANCOUVER, Wash. and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Today, Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research center, to discover and develop novel therapeutics using generative AI for up to six programs. Under the terms of the collaboration, Absci and MSK’s world-renowned cancer research teams will co-develop therapeutics using Absci’s Integrated Drug Creation™ platform.
“MSK has an incredible record of groundbreaking translational and clinical innovations in oncology,” said Sean McClain, Founder & CEO of Absci. “By combining MSK’s research expertise with our generative AI drug creation platform, we have the potential to unlock critical advances toward treating this devastating disease.”
“At MSK, we are committed to continuous innovation as we strive toward our mission of ending cancer for life, and we expect cancer care AI to play an increasingly important role,” said Gregory Raskin, MD, Senior Vice President of Technology Development at MSK. “We look forward to collaborating with Absci in leveraging the company’s generative AI platform in our ongoing efforts to advance cancer research and develop new therapies for our patients.”
The new collaboration adds to Absci’s roster of research and drug development collaborations designed to develop novel biologics for debilitating diseases. In the last year, Absci has joined forces with global pharma leaders and research institutes, including AstraZeneca and Almirall, alongside existing collaborations with Merck, NVIDIA and others. In addition to drug creation partnerships, Absci continues to develop a pipeline of internal drug candidates, including ABS-101, a potential best-in-class anti-TL1A antibody, designed and optimized using generative AI.
About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Absci Forward-Looking Statements Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding the capabilities of our Integrated Drug Creation platform, our technology development efforts and the application of those efforts, the potential benefits of our partnership with MSK, the success of our partnerships and the ability to generate advancements towards treating disease using generative AI drug creation to accelerate the development of novel candidate therapies, the anticipated value to us under our partnerships, and our internal therapeutic asset programs, the progress, milestones and success of our internal asset programs, including the potential best-in-class profile of our ABS-101 asset program, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners, our dependence on third parties to support our internal development programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements, and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
